(Q37137960)

18 August 2017

1 reference

title

Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia (English)

1 reference

18 August 2017

1 reference

2

Pierre Fenaux

1 reference

18 August 2017

Thorsten Braun

1

1 reference

PubMed ID

18410457

18 August 2017

language of work or name

English

0 references

publication date

10 April 2008

1 reference

British Journal of Haematology

18 August 2017

1 reference

18 August 2017

141

1 reference

18 August 2017

5

1 reference

18 August 2017

576-586

1 reference

Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasartrade mark, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry

18 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Lipid posttranslational modifications. Farnesyl transferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Proteins regulating Ras and its relatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

21 January 2018

Phosphoinositide kinases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

p21ras is modified by a farnesyl isoprenoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Protein prenylation: from discovery to prospects for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

The ups and downs of MEK kinase interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

A tagging-via-substrate technology for detection and proteomics of farnesylated proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Farnesyltransferase inhibitors. Preclinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Ras farnesyltransferase: a new therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Inhibition of farnesyltransferase prevents collagen-induced arthritis by down-regulation of inflammatory gene expression through suppression of p21(ras)-dependent NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Geranylgeranyltransferase I as a target for anti-cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Rational design of Ras prenyltransferase inhibitors as potential anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Inhibitors of Ras farnesyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor model: role of Ha-ras mutations and use of microarray analysis in identifying potential targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07099.X

10.1111/J.1365-2141.2008.07099.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18410457